Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-16 Sale | 2024-10-17 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $16 | $200,000 | 815,529 (Indirect Direct) | View |
| 2024-10-15 Sale | 2024-10-17 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $14.88 | $1,487,595 | 10,368,153 (Indirect Direct) | View |
| 2024-10-15 Sale | 2024-10-17 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $14.88 | $1,487,595 | 10,368,153 (Indirect Direct) | View |
| 2024-10-08 Sale | 2024-10-10 4:28 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $13.83 | $1,382,775 | 10,519,106 (Indirect Direct) | View |
| 2024-10-08 Sale | 2024-10-10 4:27 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $13.83 | $1,382,775 | 10,519,106 (Indirect Direct) | View |
| 2024-09-18 Sale | 2024-09-19 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $14 | $140,000 | 600,281 (Direct) | View |
| 2024-09-17 Sale | 2024-09-19 4:29 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $12.93 | $1,293,205 | 10,518,153 (Indirect Direct) | View |
| 2024-09-17 Sale | 2024-09-19 4:26 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $12.93 | $1,293,205 | 10,518,153 (Indirect Direct) | View |
| 2024-09-10 Sale | 2024-09-12 4:25 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $11.5 | $1,149,775 | 10,669,106 (Indirect Direct) | View |
| 2024-09-10 Sale | 2024-09-12 4:24 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $11.5 | $1,149,775 | 10,669,106 (Indirect Direct) | View |
| 2024-08-26 Sale | 2024-08-28 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Thompson Peter A. Director | 83,695 | $13 | $1,088,035 | 8,288,510 (Indirect) | View |
| 2024-08-26 Sale | 2024-08-28 4:26 pm | ARS Pharmaceuticals Inc. | SPRY | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC ORBIMED CAPITAL LLC Director | 83,695 | $13 | $1,088,035 | 8,288,510 (Indirect) | View |
| 2024-08-21 Sale | 2024-08-23 6:41 pm | ARS Pharmaceuticals Inc. | SPRY | Thompson Peter A. Director | 868,682 | $13.24 | $11,497,963 | 8,372,205 (Indirect) | View |
| 2024-08-21 Sale | 2024-08-23 6:38 pm | ARS Pharmaceuticals Inc. | SPRY | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC ORBIMED CAPITAL LLC Director | 868,682 | $13.24 | $11,497,963 | 8,372,205 (Indirect) | View |
| 2024-08-20 Sale | 2024-08-21 6:51 pm | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 50,000 | $15 | $750,000 | 67,852 (Direct) | View |
| 2024-08-19 Sale | 2024-08-21 6:51 pm | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $14 | $140,000 | 610,281 (Direct) | View |
| 2024-08-20 Sale | 2024-08-21 6:49 pm | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $16 | $200,000 | 828,029 (Direct) | View |
| 2024-08-20 Sale | 2024-08-21 6:48 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $15.03 | $1,502,587 | 10,668,153 (Indirect Direct) | View |
| 2024-08-20 Sale | 2024-08-21 6:47 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $15.03 | $1,502,587 | 10,668,153 (Indirect Direct) | View |
| 2024-08-13 Sale | 2024-08-15 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 30,000 | $13 | $390,000 | 117,852 (Direct) | View |
| 2024-08-13 Sale | 2024-08-15 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $12.48 | $1,247,555 | 10,819,106 (Indirect Direct) | View |
| 2024-08-13 Sale | 2024-08-15 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $12.48 | $1,247,555 | 10,819,106 (Indirect Direct) | View |
| 2024-07-16 Sale | 2024-07-18 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $11.4 | $1,140,295 | 10,818,153 (Indirect Direct) | View |
| 2024-07-16 Sale | 2024-07-18 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $11.4 | $1,140,295 | 10,818,153 (Indirect Direct) | View |
| 2024-07-09 Sale | 2024-07-11 5:04 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $9.6173 | $961,725 | 10,969,106 (Indirect Direct) | View |
| 2024-07-09 Sale | 2024-07-11 5:03 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $9.6173 | $961,725 | 10,969,106 (Indirect Direct) | View |
| 2024-06-11 Sale | 2024-06-13 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Lowenthal Richard E PRESIDENT AND CEO 10% Owner | 100,000 | $9.1392 | $913,917 | 11,019,106 (Indirect Direct) | View |
| 2024-06-11 Sale | 2024-06-13 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Tanimoto Sarina CHIEF MEDICAL OFFICER 10% Owner | 100,000 | $9.1392 | $913,917 | 11,019,106 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-16 Exercise | 2024-10-17 4:30 pm | N/A 2032-02-29 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $0 | 815,529 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-17 4:30 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $1.5 | 815,529 (Direct) | View |
| 2024-09-18 Exercise | 2024-09-19 4:30 pm | N/A 2032-05-23 | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $0 | 600,281 (Direct) | View |
| 2024-09-18 Exercise | 2024-09-19 4:30 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $1.5 | 600,281 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:51 pm | N/A 2028-11-28 | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 50,000 | $0 | 67,852 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:51 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 50,000 | $0.64 | 67,852 (Direct) | View |
| 2024-08-19 Exercise | 2024-08-21 6:51 pm | N/A 2032-05-23 | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $0 | 610,281 (Direct) | View |
| 2024-08-19 Exercise | 2024-08-21 6:51 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Karas Eric Chief Commercial Officer | 10,000 | $1.5 | 610,281 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:49 pm | N/A 2032-02-29 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $0 | 828,029 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:49 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $1.5 | 828,029 (Direct) | View |
| 2024-08-13 Exercise | 2024-08-15 4:30 pm | N/A 2028-11-28 | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 30,000 | $0 | 117,852 (Direct) | View |
| 2024-08-13 Exercise | 2024-08-15 4:30 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Dorsey Brian Chief Operating Officer | 30,000 | $0.64 | 117,852 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:13 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 40,000 | $0 | 40,000 (Indirect) | View |
| 2024-06-20 Option Award | 2024-06-24 5:06 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Dadoo Rajeev Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Shawver Laura Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | SCHNEIDER PHILLIP M Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Islam Saqib Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Kelly Michael Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | Thompson Peter A. Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-20 Option Award | 2024-06-24 5:00 pm | N/A 2034-06-19 | ARS Pharmaceuticals Inc. | SPRY | SAUNDERS BRENT L Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-06-13 Gift | 2024-06-17 6:39 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Director | 1,332,900 | $0 | 4,824,554 (Indirect) | View |
| 2024-06-07 Gift | 2024-06-07 9:11 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Director 10% Owner | 1,332,950 | $0 | 6,157,454 (Indirect) | View |
| 2024-06-04 Other(A) | 2024-06-07 9:09 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Shah Pratik Pratik Shah Living Trust dated June 15 2011 Director 10% Owner | 2,665,800 | $0 | 10,156,204 (Indirect) | View |